Since Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd. in 2017, our executive team has included individuals and reflected values from both companies.
President & CEO, Upsher-Smith Laboratories, LLC
As President and Chief Executive Officer, Rusty Field is responsible for the strategic direction, operating performance and growth of Upsher-Smith Laboratories. He is driven by an unwavering commitment to the company vision of helping improve the health and lives of patients through high-quality products.
Rusty joined Upsher-Smith in 2014 after five years with United Healthcare and 20 years with Ameriprise Financial, where he held senior executive sales, marketing and general management positions.
Rusty is also a member of the company’s Board of Directors, along with senior executives from Sawai Pharmaceutical Co., Ltd., which acquired Upsher-Smith in 2017.
Rusty holds a B.A. in Economics from Williams College in Williamstown, Massachusetts.
Chairman of the Board, Upsher-Smith Laboratories, LLC
As Chairman of the Board for Upsher-Smith Laboratories, LLC, Kenzo Sawai is the most senior Sawai executive serving on-site at Upsher-Smith. He works with Upsher-Smith President & CEO Rusty Field to lead strategy and decision-making for the U.S. pharmaceutical company.
Kenzo became Chairman in June 2017, upon Sawai Pharmaceutical’s acquisition of Upsher-Smith Laboratories. Before that, he served as Vice President of Corporate Strategy at Sawai, having joined his family’s business in 2001. Within the Japanese generic pharmaceutical industry, Kenzo currently serves as a permanent representative of the NIH Pricing Committee of The Federation of Pharmaceutical Manufacturers’ Associations of JAPAN.
Kenzo earned a Master’s Degree in Pharmaceutical Science from the graduate school of Kyoto University.
Vice Chairman of the Board, Upsher-Smith Laboratories, LLC
As Vice Chairman of the Board for Upsher-Smith Laboratories, LLC, Masahiro Sasaki is a senior Sawai executive serving on-site at Upsher-Smith. His chief responsibility involves helping identify, lead and manage in-licensing and joint development partnerships and projects for new drug products.
Masahiro became Vice Chairman in June 2017, upon Sawai Pharmaceutical’s acquisition of Upsher-Smith Laboratories. He also serves as Senior Executive Officer of Overseas Business at Sawai, having joined the company in 2013. Before that, he served in numerous medical and healthcare business roles for 37 years at Sumitomo Corp., which also currently owns a stake in Upsher-Smith.
Masahiro earned a Bachelor of Science in Pharmaceutical Science from The University of Tokyo.